Cambridge, MA – March 5, 2025 – Today, Insilico Medicine, a clinical-stage biotechnology company pioneering generative AI for drug discovery and development, announced the deployment of the first bipedal humanoid in its AI-powered fully-robotic drug discovery laboratory. The humanoid, called “Supervisor” will be used for data acquisition and data generation for training of the embodied AI systems to learn the skills of human laboratory scientists. The work will be conducted by the Insilico Robotics team at Insilico Medicine. The humanoid will also immediately assist with lab tours, telepresence, tracking and lab supervision. 

Early menopause may raise the risk of type 2 diabetes, but supporting evidence remains limited. In a recent study, researchers from Korea University examined health data from over 1.1 million postmenopausal women in Korea to explore this association. Their analysis revealed that women who experienced menopause before age 40 faced a higher risk of type 2 diabetes than those with menopause at 50 or later, emphasizing targeted prevention strategies.